8-K: PDS Biotech Announces Positive Clinical Data in JAMA Oncology: Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers

PDS Biotechnology announces the publication of positive clinical data in JAMA Oncology, showcasing promising survival and clinical responses in patients with recurrent/metastatic HPV-associated cancers treated with a triple combination therapy.

Summary

• PDS Biotechnology Corporation announced the publication of clinical results in the Journal of the American Medical Association (JAMA) Oncology.
• The article highlights the promising clinical responses observed with the triple combination of Versamune HPV, PDS01ADC, and a PD-L1 immune checkpoint inhibitor (ICI) in patients with recurrent/metastatic HPV-associated cancers.
• The trial included patients with anal, cervical, head and neck, penile, vaginal, and vulvar cancers.
• In immune checkpoint inhibitor (ICB) naive patients, the median overall survival (mOS) was 42.4 months, compared to a historically published result of 7-12 months.
• In HPV16-positive ICB naive patients, the objective response rate (ORR) was 75%, compared to a historically published result of 12-24%.
• In ICB-resistant patients, the median overall survival (mOS) was 17 months, compared to a historically published result of 3-4 months.
• The confirmed objective response rate (ORR) in HPV16-positive ICB-resistant patients who received a high dose of PDS01ADC was 62.5%.

Sentiment

Score: 8

Explanation: The document presents highly positive clinical trial results, indicating a significant improvement in patient outcomes compared to existing treatments. While adverse events are noted, the overall tone is optimistic due to the substantial survival and response rate benefits.

Positives

• The triple combination therapy shows significant improvement in median overall survival for both ICB-naive and ICB-resistant patients compared to historical results.
• The objective response rate in HPV16-positive ICB-naive patients is notably high.
• The study validates the potential of Versamune HPV and PDS01ADC in treating advanced, refractory cancers.
• The results support continued investigation of both agents in ongoing and future clinical trials.

Negatives

• Grade 3 and 4 treatment-related adverse events occurred in 52% of patients, and toxicity correlated with the dose of PDS01ADC and BA.

Risks

• The Company's dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates.
• The risk that raising such additional capital may restrict the Company's operations or require the Company to relinquish rights to the Company's technologies or product candidates.
• The timing for the Company or its partners to initiate the planned clinical trials for Versamune HPV, PDS01ADC and other Versamune based product candidates.
• The future success of such trials.
• The successful implementation of the Company's research and development programs and collaborations, including any collaboration studies concerning Versamune HPV, PDS01ADC and other Versamune based product candidates and the Company's interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company's product candidates.

Future Outlook

PDS Biotech plans to initiate a pivotal clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers and will begin their VERSATILE-003 Phase 3 trial of Versamune HPV + pembrolizumab in recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma next month.

Management Comments

• Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, stated that the results underscore the clinical potential of Versamune HPV when used in combination with PDS01ADC and an ICI in transforming the treatment paradigm for HPV-associated cancers.
• Kirk Shepard, M.D., PDS Biotech's Chief Medical Officer, added that the published research in JAMA Oncology further validates the quality of the trial and their platforms and that the data supports continued investigation of both agents in several ongoing and future clinical trials.

Industry Context

The announcement highlights the growing importance of targeted immunotherapies in treating HPV-associated cancers, particularly in cases where patients have developed resistance to immune checkpoint inhibitors. The combination approach addresses a critical unmet need in this patient population.

Comparison to Industry Standards

• The median overall survival of 42.4 months in ICB-naive patients treated with the triple combination therapy significantly exceeds the historical 7-12 months reported with standard-of-care immune checkpoint inhibitors.
• The 75% objective response rate in HPV16-positive ICB-naive patients is substantially higher than the 12-24% typically observed with standard-of-care immune checkpoint inhibitors.
• In ICB-resistant patients, the median overall survival of 17 months surpasses the historical 3-4 months, indicating a potential breakthrough in treating this challenging patient group.
• Competitors like Merck (Keytruda) and Bristol Myers Squibb (Opdivo) have established ICIs as standard treatments, but PDS Biotech's combination therapy shows promise in improving outcomes, especially in resistant cases.

Stakeholder Impact

• Shareholders: Positive clinical data may increase investor confidence and potentially raise the company's stock value.
• Patients: The triple combination therapy offers a potential new treatment option with improved survival rates for recurrent/metastatic HPV-associated cancers.
• Employees: Successful clinical trials can boost employee morale and job security.
• Partners: Positive results may strengthen collaborations and attract new partnerships.

Next Steps

• Initiation of VERSATILE-003 Phase 3 trial of Versamune HPV + pembrolizumab in recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma.
• Continued investigation of Versamune HPV and PDS01ADC in ongoing and future clinical trials.

Key Dates